Founders Financial Alliance’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$475K Sell
1,064
-37
-3% -$17.3K 0.09% 220
2025
Q4
$499K Buy
1,101
+56
+5% +$24.1K 0.09% 197
2025
Q3
$409K Buy
1,045
+226
+28% +$94.5K 0.08% 236
2025
Q2
$365K Sell
819
-49
-6% -$22.6K 0.08% 225
2025
Q1
$421K Buy
+868
New +$404K 0.1% 203
2024
Q1
Sell
-1,136
Closed -$462K 575
2023
Q4
$462K Sell
1,136
-440
-28% -$163K 0.18% 112
2023
Q3
$548K Sell
1,576
-72
-4% -$25.2K 0.24% 94
2023
Q2
$580K Buy
1,648
+88
+6% +$29.6K 0.23% 94
2023
Q1
$507K Sell
1,560
-44
-3% -$13.2K 0.25% 95
2022
Q4
$463K Sell
1,604
-20
-1% -$6.09K 0.21% 109
2022
Q3
$470K Buy
+1,624
New +$467K 0.24% 99
2022
Q1
Sell
-2,487
Closed -$546K 482
2021
Q4
$546K Buy
+2,487
New +$484K 0.22% 105
2021
Q3
Sell
-2,361
Closed -$477K 483
2021
Q2
$477K Buy
2,361
+94
+4% +$19.7K 0.22% 107
2021
Q1
$488K Buy
2,267
+340
+18% +$74.7K 0.24% 92
2020
Q4
$456K Buy
1,927
+1,883
+4,280% +$432K 0.26% 90
2020
Q3
$12K Buy
+44
New +$12.1K 0.01% 728

Other funds holding VRTX

Founders Financial Alliance's VRTX Position: Q1 2026 in Review

Founders Financial Alliance reduced its Vertex Pharmaceuticals (VRTX) stake by 3.4% in Q1 2026, selling an estimated $17.3K and leaving 1,064 shares worth $475K. The position accounts for 0.09% of the portfolio, ranked #220.

Founders Financial Alliance first reported a position in VRTX in Q3 2020 and has held it in 16 quarters since. The position peaked at $580K in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Founders Financial Alliance held 1,064 shares of Vertex Pharmaceuticals worth $475K as of Q1 2026.
  • Founders Financial Alliance sold 37 Vertex Pharmaceuticals shares in Q1 2026, an estimated $17.3K.
  • Vertex Pharmaceuticals made up 0.09% of Founders Financial Alliance's portfolio in Q1 2026, its #220 holding.
  • Founders Financial Alliance first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • Founders Financial Alliance's Vertex Pharmaceuticals position peaked at $580K in Q2 2023.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Founders Financial Alliance's 13F filing for Q1 2026, filed 11 May 2026.